Literature DB >> 9566805

Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis.

K A Kobak1, J H Greist, J W Jefferson, D J Katzelnick, H J Henk.   

Abstract

The goal of the study was to provide a quantitative analysis of the relative efficacy of all five currently available serotonin reuptake inhibitors (SRIs) and behavior therapy [exposure and response prevention (ERP)] for obsessive compulsive disorder. The relationship between effect size and methodological characteristics was also empirically examined. A search was conducted of several computerized databases covering the dates from 1973 to 1997. Seventy-seven studies were identified, yielding 106 treatment comparisons involving 4641 patients. Effect sizes were analyzed between individual interventions and between intervention class [SRI, ERP or the combined treatment of an SRI with ERP(ERP/SRI)]. Data were analyzed both before and after controlling for methodological variables. The effect size for clomipramine (CMI) was significantly greater than the other SRIs, with the exception of fluoxetine (FLX). CMI was not significantly greater than ERP or ERP/SRI. As a class, ERP was significantly greater than SRIs as a whole. Effect sizes were larger for studies without a control group or random assignment, for self-reported outcome measures, and varied significantly by method of effect size calculation. Year of publication was significantly related to effect size. When controlling for these methodological variables, CMI was not significantly greater than FLX or fluvoxamine (FLV), and ERP was no longer significantly greater than the SRIs as a whole. No significant difference was found between CMI and the other SRIs as a group in head to head trials. No differences in drop-out rates were found. CMI stands out from the other SRIs. This difference is probably not clinically significant enough to warrant first choice treatment, given CMI's greater lethality in overdose. The choice between an SRI or ERP is dominated primarily by the infrequent availability of ERP and to a lesser degree by personal preference. Methodological differences significantly impact effect size.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566805     DOI: 10.1007/s002130050558

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

Review 1.  Obsessive compulsive disorder.

Authors:  G Mustafa Soomro
Journal:  BMJ Clin Evid       Date:  2012-01-18

2.  A randomized clinical trial of a brief family intervention to reduce accommodation in obsessive-compulsive disorder: a preliminary study.

Authors:  Johanna Thompson-Hollands; Amitai Abramovitch; Martha C Tompson; David H Barlow
Journal:  Behav Ther       Date:  2014-11-11

3.  Interventions for obsessive compulsive symptoms in people with schizophrenia.

Authors:  Mohan Raj; Saeed Farooq
Journal:  Cochrane Database Syst Rev       Date:  2005

Review 4.  Cognitive behavioral therapy for obsessive-compulsive disorder: an update.

Authors:  Jonathan D Huppert; Martin E Franklin
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

5.  Sleep in obsessive compulsive disorder: polysomnographic studies under baseline conditions and after experimentally induced serotonin deficiency.

Authors:  Ulrich Voderholzer; Dieter Riemann; Christine Huwig-Poppe; Anne Katrin Kuelz; Andreas Kordon; Katharina Bruestle; Mathias Berger; Fritz Hohagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-12-05       Impact factor: 5.270

Review 6.  Minority participation in randomized controlled trials for obsessive-compulsive disorder.

Authors:  Monnica Williams; Mark Powers; Yeo-Gin Yun; Edna Foa
Journal:  J Anxiety Disord       Date:  2010-03

Review 7.  Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.

Authors:  Anjali L Varigonda; Ewgeni Jakubovski; Michael H Bloch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-08-04       Impact factor: 8.829

8.  Current trends in drug treatment of obsessive-compulsive disorder.

Authors:  Eric H Decloedt; Dan J Stein
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Chem Genomics       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.